Search

Your search keyword '"Chang, J.H.C."' showing total 20 results
Start Over Author "Chang, J.H.C."
20 results on '"Chang, J.H.C."'

1. Treatment of Thymoma and Thymic Carcinoma with Proton Beam Therapy: Outcomes from the Proton Collaborative Group Prospective Registry

Author

Tian, S., primary, McCook, A., additional, Choi, I.J., additional, Simone, C.B., additional, Vargas, C.E., additional, Yu, N.Y., additional, Chang, J.H.C., additional, Mihalcik, S.A., additional, Tsai, H., additional, Zeng, J., additional, Rosen, L.R., additional, Rana, Z.H., additional, Urbanic, J.J., additional, Stokes, W.A., additional, Kesarwala, A.H., additional, Bradley, J.D., additional, and Higgins, K.A., additional

Published
2023
Full Text
View/download PDF

2. Multi-Institutional Experience of Proton Therapy for Rhabdomyosarcoma and Ewing Sarcoma in the Proton Collaborative Group (PCG) Prospective Registry

Author

Von Werne, K., primary, Mair, K., additional, Fader, M.E., additional, DeAngulo, G., additional, Eiseler, N., additional, Kalman, N.S., additional, Press, R.H., additional, Daghistani, D., additional, Jimenez, R., additional, Paraliticci, G., additional, Pretell, J., additional, Chang, J.H.C., additional, Vern-Gross, T.Z., additional, Mihalcik, S.A., additional, Kwok, Y., additional, Tsai, H.K., additional, Zeng, J., additional, Rotondo, R., additional, Wolden, S.L., additional, and Hall, M.D., additional

Published
2023
Full Text
View/download PDF

3. Multi-Institutional Experience of Proton Therapy for Osteosarcoma in the Proton Collaborative Group (PCG) Prospective Registry

Author

Mair, K., primary, Von Werne, K., additional, Kalman, N.S., additional, Eiseler, N., additional, Jimenez, R., additional, Paraliticci, G., additional, Pretell, J., additional, Press, R.H., additional, Chang, J.H.C., additional, Vern-Gross, T.Z., additional, Mihalcik, S.A., additional, Zeng, J., additional, Kwok, Y., additional, Tsai, H.K., additional, Simone, C.B., additional, Chuong, M.D., additional, and Hall, M.D., additional

Published
2023
Full Text
View/download PDF

4. Toxicity Comparison of Whole Pelvic vs. Prostate Only Proton Therapy - Results from the Proton Collaborative Group PCG 001-09.

Author

Raghavan, A., Chang, J.H.C., Mihalcik, S.A., Tsai, H., Rosen, L.R., Zeng, J., Mishra, M., Vargas, C.E., Sebastian, N., Rossi, C.J., Chhabra, A.M., Choi, I.J., Simone II, C.B., and Hasan, S.

Subjects
*PROSTATE cancer patients, *PHOTON emission, *PROTON therapy, *CONFOUNDING variables, *PROSTATE
Abstract

Whole pelvis (WP) radiation with photons is associated with higher toxicity in prostate cancer patients compared to prostate radiation alone. Such differential toxicity has not been defined with proton therapy (PT). We hypothesize PT can mitigate a significant differential in toxicity between WP and prostate only irradiation. Using the Proton Collaborative Group prospective registry (NCT01255748), we compared the acute and late gastrointestinal and genitourinary toxicity of proton therapy (PT) delivered to the prostate only versus WP PT. Parameters that predicted for adverse events (AEs) were assessed using univariable and multivariable binomial regression analysis. A total of 6473 patients with prostate cancer were included with an enrollment period from 7/2009 to 9/2023 and a median follow-up of 21 months. 874 patients were treated with WP PT while 5599 received radiation to the prostate alone. The median baseline International Prostate Symptom Score (IPSS) was 7 and the median age was 68 (IQR 64-73). Patients less likely to receive WP PT include those with higher BMI (OR = 0.98; p < 0.001), hypofractionated treatments (OR: 0.72; p = 0.01), and rectal balloon placement (OR: 0.21; p < 0.001). Acute grade 2 GU AEs occurred in 22.1% of patients when treated with prostate-only PT compared to 27.5% with WP PT (OR: 1.36; CI 1.12-1.64; p = 0.001). Conversely, 11.7% of WP-PT patients developed late GU grade 2 AEs compared to 18.1% in prostate-only patients (OR: 0.6; CI: 0.47-0.77; p < 0.001). Among patients who received prostate-only PT, 5.1% had late grade 2 GI AEs compared to 3.1% with WP PT (OR: 0.61; CI: 0.39-0.96; p = 0.032). The rate of grade 3 GU AEs were 0.6% and 0.8% in prostate only and WP PT cohorts, respectively. The rate of grade 3 GI AEs were 0.5% and 1.0% in prostate only and WP PT cohorts, respectively. There were no statistical differences between cohorts for grade 3 AEs. There was no difference in any AE parameter between WP and prostate-only PT with multivariable regression. Lower IPSS score correlated with reduced toxicity in both acute grade 2 (OR: 0.048; CI: 1.00-1.07; p < 0.001) and late grade 2 GU conditions (OR: 0.0497; CI: 1.04-1.06; p < 0.001). Rectal balloon placement was associated with acute grade 2 GU (OR: 2.14; CI: 1.65-2.78; p < 0.001), late grade 2 GU (OR: 2.25; CI: 1.65-3.08; p < 0.001), and late grade 2 GI (OR: 3.09; CI: 1.66-5.78; p < 0.001) AE conditions. After adjustment for confounding variables, there appears to be no additional toxicity risk associated with WP compared to prostate only radiation with PT. Further evaluation is warranted to confirm these findings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Randomized Phase III Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate: Analysis of Quality of Life and Toxicity, PCG GU 003

Author

Thorpe, C.S., primary, DeWees, T.A., additional, Bhangoo, R.S., additional, Petersen, M., additional, Chang, J.H.C., additional, Hartsell, W.F., additional, Sinesi, C.C., additional, Rwigema, J.C., additional, Keole, S.R., additional, Gondi, V., additional, and Vargas, C.E., additional

Published
2021
Full Text
View/download PDF

8. Selection of Mediastinal Lymphoma Patients for Proton Therapy in a Prospective Multi-Institutional Registry: Concordance with the ILROG Guidelines

Author

Tseng, Y.D., primary, Mohindra, P., additional, Pankuch, M., additional, McGee, L.A., additional, Rossi, C.J., additional, Flampouri, S., additional, Hajj, C., additional, Molitoris, J.K., additional, Chang, J.H.C., additional, Tsai, H.K., additional, Stevens, C.W., additional, Rosen, L.R., additional, Vargas, C.E., additional, and Hartsell, W.F., additional

Published
2020
Full Text
View/download PDF

9. Toxicity, Disease Control, and Survival Following Proton Therapy-Fractionated Re-Irradiation for Recurrent Intracranial Meningioma Not Amenable to Radiosurgery

Author

Lynch, C., primary, Hartsell, W.F., additional, Chang, J.H.C., additional, Sweeney, P.J., additional, Kalapurakal, J.A., additional, Diaz, A.Z., additional, Chandler, J.P., additional, Tsung, A.J., additional, Prabhu, V., additional, Bovi, J.A., additional, Connelly, J.M., additional, Grimm, S., additional, Raizer, J.J., additional, Sarma, K., additional, Conterato V, D.J., additional, Rajendran, R.R., additional, and Gondi, V., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results